Chemotherapy: Open Access

Chemotherapy: Open Access
Open Access

ISSN: 2167-7700

Review Article - (2015) Volume 4, Issue 1

Synergistic Effect between Baicalein and Antibiotics against Clinic Methicillin and Vancomycin-Resistant Staphylococcus aureus

Young-Soo Lee1, Eun-Kyung Jung2 and Jeong-Dan Cha3*
1Department of Dental Hygiene, Sun Moon University, Asan-si 336-708, Republic of Korea
2Department of Dental Hygiene, Ulsan College, Ulsan, South Korea
3Department of Research Development, Institute of Jinan Red Ginseng, Jinan 567-801, Republic of Korea
*Corresponding Author: Jeong-Dan Cha, Department of Natural Product Research, Institute of Jinan red ginseng, 520-9 Banwol-ri, Jinan-eup, Jinan-gun, Jeollabuk-do, 567-801, Republic of Korea, Tel: +82-63-432-0913, Fax: +82-63-432-0910 Email:

Abstract

Baicalein is one of the major flavonoids in Scutellaria baicalensis Georgi, which has long been used in several biological effects, such as antiviral, anti-inflammation, anti-hepatotoxicity, and anti-tumor properties, have been reported. In this study, baicalein demonstrated strong antibacterial activity against clinic isolated methicillin and vancomycin-resistant Staphylococcus aureus (MRSA and VRSA) in this experiment. Baicalein was determined against clinic isolated MRSA 1-16 with MIC and MBC values ranging from 64 to 256 and 64 to 512 μg/ml; for MSSA 1-2 from 128 and 256 μg/ml and 128 and 512 μg/ml; for VRSA 1-2 from 64 and 128 μg/ml and 64 and 512 μg/ml, respectively. The range of MIC50 and MIC90 of baicalein were 16-64 μg/ml and 64-256 μg/ml, respectively. The combination effects of baicalein with antibiotics were synergistic (FIC index <0.5) against most of tested clinic isolated MRSA, MSSA, and VRSA except additive, MRSA 7 in oxacillin and MRSA 8 and 15 in vancomycin (FIC index <0.625-0.75). Furthermore, a time-kill study showed that the growth of the tested bacteria was completely attenuated after 2-6 h of treatment with the ½ MIC of baicalein, regardless of whether it was administered alone or with ampicillin, oxacillin, or vacomycin. The results suggest that baicalein could be employed as a natural antibacterial agent against multidrug-resistant pathogens infection.

Keywords: Baicalein, Antibacterial activity, Methicillin-resistant Staphylococcus aureus (MRSA), Vacomycin-Resistant Staphylococcus aureus (VRSA), Checker board method, Time-kill method

Introduction

Staphylococcus aureus (S. aureus) is an important human pathogen, causing life-threatening systemic infections such as pneumonia, septicemia, endocarditis, and osteomyelitis [1,2]. By the end of the 1990s the relatively few multidrug-resistant and highly epidemic clones of Methicillin-Resistant Staphylococcus aureus (MRSA) had become the most frequent causative agents of S. aureus disease in both hospitals and communities [3]. In spite of the availability of several structurally different antibacterial agents, the therapy most frequently used for treatment of MRSA infections has remained the glycopeptides antibiotics, primarily vancomycin [4,5]. From 1980 on, there was an abrupt and continued increase in the use of vancomycin in the United States and several countries, which seems to parallel the increasing frequency of MRSA infections in hospitals [5,6]. This illustrates the enormous selective pressure highly focused on MRSA strains worldwide. Contrary to methicillin-susceptible S. aureus (MSSA), MRSA tend to be multi-drug resistant (MDR), that is, resistant not only to β-lactam antibiotics but also to a wide range of different antibiotic classes, such as fluoroquinolones, tetracycline’s, macrolides, lincosamides, and aminoglycosides, and even strains of vancomycin intermediate susceptible or full resistant (VISA and VRSA, respectively) have emerged [5-7]. Antimicrobial drugs effective for treatment of patients infected with MRSA are limited. Hence, search for novel antimicrobial compounds or alternative therapy for these infections is inevitable.

Plant medicines are used on a worldwide scale to prevent and treat infectious diseases. They are of great demand both in the developed as well as developing countries for the primary health care needs due to their wide biological and medicinal activities, higher safety margin and lesser costs [8,9]. Plants are rich in a wide variety of secondary metabolites such as tannins, alkaloids, terpenoids and flavonoids having been found in vitro since they have antimicrobial properties and may serve as an alternative, effective, cheap and safe antimicrobial for the treatment of microbial infections [10-14]. Baicalein (5,6,7- trihydroxyflavone), a flavonoid originally isolated from the root of Scutellaria baicalensis Georgi, has numerous pharmacological activities, such as anti-fibrotic, anti-virus, anti-bacterial, anti-fungal, anti-oxidant, anti-cancer, and anti-inflammatory activities [15-20]. It has been shown to significantly restore the effectiveness of β-lactam antibiotics and tetracycline against methicillin-resistant Staphylococcus aureus (MRSA) [21]. With multiple therapeutic benefits, the antibacterial actions of baicalein also are involved in overcoming other bacterial resistance mechanisms [21,22]. In gramnegative bacteria, baicalein is shown to reverse the resistance in TetK overexpressing Escherichia coli by inhibiting tetracyclin efflux by TetK [21].

In this study, the antimicrobial activities of baicalein against methicillin and vancomycin-resistant Staphylococcus aureus isolated in a clinic were assessed using broth micro-dilution method and the checkerboard and time-kill methods for synergistic effectof the combination with antibiotics.

Material

Preparation of bacterial strains

16 isolates of methicillin-resistant Staphylococcus aureus, 2 isolates of methicillin-sensitive S. aureus (MSSA), and 2 isolates of Vancomycin-Resistant S. Aureus (VRSA) purchased from the Culture Collection of Antimicrobial Resistant Microbes (CCARM), as well as standard strains of methicillin-sensitive S. aureus (MSSA) ATCC 25923 and methicillin-resistant S. aureus (MRSA) ATCC 33591 were used (Table 1). Antibiotic susceptibility was determined in testing the inhibition zones (inoculums 0.5 McFarland suspension, 1.5 × 108 CFU/ml) and MIC/MBC (inoculums 5 × 105 CFU/ml) for strains, measured as described in the National Committee for Clinical Laboratory Standards (NCCLS, 1999). Briefly, the growth of bacteria was examined at 37°C in 0.95 ml of BHI broth containing various concentrations of baicalein. These tubes were inoculated with 5 × 105 colony-forming units (CFU)/ml of an overnight culture grown in BHI broth, and incubated at 37°C. After 24 h of incubation, the optical density (OD) was measured spectro-photometrically at 600 nm. Three replicates were measured for each concentration of tested drugs.

Samples Baicalein (μg/ml) Ampicillin Oxacillin Vancomycin
MIC50< MIC90< MIC/MBC MIC/MBC (μg/ml)
MSSA  ATCC 25923 1 32 128 128/256 16-Aug 0.25/0.5 0.5/0.5
MRSA  ATCC 33591 2 64 256 256/512 512/2048 16/32 4-Feb
VRSA 3A0633 32 128 128/512 1024/2048 512/1024 32/64
VRSA 3A0664 16 64 64/64 64/256 256/1024 32/64
MSSA 15 32 128 128/128 512/1024 0.5/0.5 2-Jan
MSSA2 32 256 256/512 256/512 0.5/2 2-Jan
MRSA 1 64 256 256/512 128/256 128/256 2-Jan
MRSA 2 32 128 128/512 128/256 16/32 4-Jan
MRSA 3 16 64 64/256 128/512 128/512 4-Feb
MRSA 4 16 64 64/128 256/512 512/2048 1-Jan
MRSA 5 32 256 256/512 128/512 512/1024 2-Jan
MRSA 6 64 256 256/512 64/128 128/256 2-Jan
MRSA 7 16 64 64/128 128/256 512/1024 2-Jan
MRSA 8 16 128 128/256 256/512 1024/2048 4-Jan
MRSA 9 64 256 256/512 64/128 512/1024 2-Jan
MRSA 10 64 256 256/256 128/256 512/512 0.5/2
MRSA 11 16 64 64/128 64/128 64/128 2-Jan
MRSA 12 16 64 64/64 256/256 128/256 0.5/4
MRSA 13 32 256 256/256 128/256 64/128 2-Jan
MRSA 14 32 256 256/512 128/256 16/32 4-Jan
MRSA 15 32 128 128/128 64/128 128/256 4-Jan
MRSA 16 64 256 256/512 128/512 256/512 0.5/1

Table 1: Antibacterial activity of baicalein and antibiotics in isolated MRSA, VRSA, MSSA, and some of reference bacteria; 1MSSA (ATCC 25923): reference strain Methicillin-sensitive Staphylococcus aureus;2 MRSA (ATCC 33591): reference strain Methicillin-resistant Staphylococcus aureus;3VRSA 3A063: Vancomycin-resistant Staphylococcus aureus isolated a clinic;4VRSA 3A066 : Vancomycin-resistant Staphylococcus aureus isolated a clinic;5MSSA (1, 2): Methicillin-sensitive Staphylococcus aureus isolated a clinic;6MRSA (1-16): Methicillinresistant Staphylococcus aureus isolated a clinic.

Methods

Minimum inhibitory concentration/minimum bactericidal concentration assay

The antimicrobial activities of baicalein against clinical isolates MRSA 16, MSSA 2, VRSA 2, and reference strains were determined via the broth dilution method [23]. The minimum inhibitory concentration (MIC) was recorded as the lowest concentration of test samples resulting in the complete inhibition of visible growth. For clinical strains, MIC50s and MIC90s, defined as MICs at which, 50 and 90%, respectively of the isolates were inhibited, were determined. The Minimum Bactericidal Concentration (MBC) was determined based on the lowest concentration of the extracts required to kill 99.9% of bacteria from the initial inoculum as determined by plating on agar.

Checkerboard dilution test

The synergistic combinations were investigated in the preliminary checkerboard method performed using the MRSA, MSSA, and VRSA of clinical isolate strains via MIC and MBC determination [24]. The Fractional Inhibitory Concentration Index (FICI) and Fractional Bactericidal Concentration Index (FBCI) are the sum of the FICs and FBCs of each of the drugs, which were defined as the MIC and MBC of each drug when used in combination divided by the MIC and MBC of each drug when used alone. The FIC and FBC index was calculated as follows: FIC=(MIC of drug A in combination/MIC of drug A alone)+ (MIC of drug B in combination/MIC of drug B alone) and FBC=(MBC of drug A in combination/MBC of drug A alone)+(MBC of drug B in combination/MBC of drug B alone). FIC and FBC indices were interpreted as follows: the FIC index was interpreted as follows: synergy, <0.5; partial synergy, 0.5-0.75; additive effect, 0.76-1.0; indifference, >1.0-4.0; and antagonism, >4.0 [23,24].

Time-kill curves

The bactericidal activities of the drugs evaluated in this study were also evaluated using time-kill curves constructed using the isolated and reference strains. Cultures with an initial cell density of 1-5 × 106 CFU/ml were exposed to the MIC of baicalein alone, or baicalein (1/2 MIC) plus oxacillin or ampicillin or vancomycin (1/2 MIC). Viable counts were conducted at 0, 0.5, 1, 2, 3, 4, 5, 6, 12, and 24 h by plating aliquots of the samples on agar and subsequent incubation for 24 hours at 37°C. All experiments were repeated several times and colony counts were conducted in duplicate, after which the means were determined.

Results

Antibacterial activity

Our results of the antibacterial activity showed that the baicalein exhibited inhibitory activities against isolates MSSA, MRSA, VRSA, and reference stains. The MICs and MBCs values of baicalein against MSSA ATCC25923 in the range of 128 μg/ml and 256 μg/ml, MRSA ATCC33591 in the range of 256 μg/ml and 512 μg/ml, and isolates MSSA 1 and 2 in the range of 128-256 μg/ml and 128-512 μg/ml, MRSA 1-16 in the ranges of 64-256 μg/ml and 64-512 μg/ml, and VRSA 1 and 2 in the range of 64-128 μg/ml and 64-512 μg/ml, respectively (Table 1). The baicalein showed the strongest activity against VRSA 3A063, MRSA 3, 4, 7, and 12 (MICs values 64 μg/ml and MBCs values 64-128 μg/ml). The ampicillin showed antibacterial activity against all tested bacteria by the MICs and MBCs ranges of 8-1024 μg/ml and 16-2048 μg/ml, oxacillin by MICs values 0.25-1024 μg/ml and MBCs values 0.5-2048 μg/mL, and vancomycin by MICs values 0.5-32 μg/ml and MBCs values 0.5-64 μg/mL (Table 1). The MIC50 and MIC90 values of baicalein for MRSA 1-16 isolates were 16-64 μg/ml and 64-256 μg/ml, respectively.

Synergistic effect of baicalein against VRSA and MRSA

The combination of oxacillin and baicalein resulted in a reduction in the MICs/MBCs for isolates VRSA 1-2 and MSSA 1-2, with the MICs/MBCs of 4/8 or 32/64 μg/ml and 16/32 or 64/128 μg/ml, for oxacillin becoming 0.125-64/0.125-256 μg/mL and reduced by ≥4-fold, evidencing a synergistic effect as defined by a FICI and FBCI of ≤ 0.5 (Table 2).

Samples Agent MIC/MBC (μg/ml) FIC/FBC FICI/FBCI2 Outcome
Alone Combination1
MSSA ATCC 25923 3 Baicalein 128/256 32/64 0.25/0.25 0.5/0.5 Synergistic/Synergistic
Oxacillin 0.25/0.5 0.0625/0.125 0.25/0.25
MRSA ATCC 33591 4 Baicalein 256/512 64/64 0.25/0.125 0.5/0.625 Synergistic/   Additive
Oxacillin 16/32 16-Apr 0.25/0.5
VRSA 3A0635 Baicalein 128/512 32/64 0.25/0.125 0.375/0.375 Synergistic/  Synergistic
Oxacillin 512/1024 64/256 0.125/0.25
VRSA 3A0666 Baicalein 64/64 8-Apr 0.0625/0.125 0.3125/0.25 Synergistic/ Synergistic
Oxacillin 256/1024 64/128 0.25/0.125
MSSA 17 Baicalein 128/128 16/32 0.125/0.25 0.375/0.5 Synergistic/ Synergistic
Oxacillin 0.5/0.5 0.125/0.125 0.25/0.25
MSSA 2 Baicalein 256/512 64/128 0.25/0.25 0.5/0.375 Synergistic/ Synergistic
Oxacillin 0.5/2 0.125/0.25 0.25/0.125
MRSA 18 Baicalein 256/512 64/128 0.25/0.25 0.5/0.5 Synergistic/
Oxacillin 128/256 32/64 0.25/0.25 Synergistic
MRSA 2 Baicalein 128/512 32/64 0.25/0.125 0.5/0.375 Synergistic/ Synergistic
Oxacillin 16/32 8-Apr 0.25/0.25
MRSA 3 Baicalein 64/256 16/64 0.25/0.25 0.5/0.375 Synergistic/
Oxacillin 128/512 32/64 0.25/0.125 Synergistic
MRSA 4 Baicalein 64/128 16/32 0.25/0.25 0.375/0.3125 Synergistic/ Synergistic
Oxacillin 512/2048 64/128 0.125/0.0625
MRSA 5 Baicalein 256/512 32/64 0.125/0.125 0.25/0.375 Synergistic/ Synergistic
Oxacillin 512/1024 64/256 0.125/0.25
MRSA 6 Baicalein 256/512 32/128 0.125/0.25 0.375/0.5 Synergistic/   Synergistic
Oxacillin 128/256 32/64 0.25/0.25
MRSA 7 Baicalein 64/128 32/64 0.5/0.5 0.625/0.625 Additive/  Additive
Oxacillin 512/1024 64/128 0.125/0.125
MRSA 8 Baicalein 128/256 32/64 0.25/0.25 0.5/0.375 Synergistic/ Synergistic
Oxacillin 1024/2048 256/256 0.25/0.125
MRSA 9 Baicalein 256/512 64/128 0.25/0.25 0.5/0.5 Synergistic/ Synergistic
Oxacillin 512/1024 128/256 0.25/0.25
MRSA 10 Baicalein 256/256 64/128 0.25/0.5 0.5/1.0 Synergistic/   Additive
Oxacillin 512/512 128/256 0.25/0.5
MRSA 11 Baicalein 64/128 16/32 0.25/0.25 0.5/0.5 Synergistic/ Synergistic
Oxacillin 64/128 16/32 0.25/0.25
MRSA 12 Baicalein 64/64 16/32 0.25/0.5 0.5/0.75 Synergistic/  Additive
Oxacillin 128/256 32/64 0.25/0.25
MRSA 13 Baicalein 256/256 64/128 0.25/0.5 0.5/0.75 Synergistic/  Additive
Oxacillin 64/128 16/32 0.25/0.25
MRSA 14 Baicalein 256/512 64/128 0.25/0.25 0.5/0.5 Synergistic/ Synergistic
Oxacillin 16/32 8-Apr 0.25/0.25
MRSA 15 Baicalein 128/128 32/64 0.25/0.5 0.5/0.75 Synergistic/  Additive
Oxacillin 128/256 32/64 0.25/0.25
MRSA 16 Baicalein 256/512 64/128 0.25/0.25 0.375/0.5 Synergistic/ Synergistic
Oxacillin 256/512 32/128 0.125/0.25

Table 2: Synergistic effects of the baicalein with oxacillin in isolated MRSA, VRSA, MSSA, and some of reference bacteria;1The MIC and MBC of baicalein with oxacillin;2 The FIC index ;3MSSA (ATCC 25923): reference strain Methicillin-sensitive Staphylococcus aureus ; 4MRSA (ATCC 33591): reference strain Methicillin-resistant Staphylococcus aureus;5VRSA 3A063: Vancomycin-resistant Staphylococcus aureus isolated a clinic;6VRSA 3A066 : Vancomycin-resistant Staphylococcus aureus isolated a clinic;7MSSA (1, 2): Methicillin-sensitive Staphylococcus aureus isolated a clinic;8MRSA (1-16): Methicillin-resistant Staphylococcus aureus isolated a clinic.

The combination of oxacillin and baicalein resulted in a reduction against isolates MRSA 1-16, with the MICs/MBCs values of 16-64/32-128 μg/ml, for oxacillin becoming 4-256/8-256 μg/ml and reduced by ≥4-fold, evidencing a synergistic effect as defined by a FICI and FBCI of ≤ 0.5 except MRSA 7 of additive (FICI ≥ 0.625) and MRSA 10, 12, 13, and 15 of additive (FBCI ≥ 0.75). The combination of ampicillin and baicalein resulted in a reduction in the MICs/MBCs for isolates VRSA 1-2 and MSSA 1-2, with the MICs/MBCs of 8/16 or 32/64 μg/ml and 16/32 or 64/128, for ampicillin becoming 16/32 or 256/256 μg/ml and 64/128 or 128/256 μg/ml and reduced by ≥4-fold, evidencing a synergistic effect as defined by a FICI and FBCI of ≤ 0.5. The combination of ampicillin and baicalein resulted in a reduction against isolates MRSA 1-16, with the MICs/MBCs values of 8-64/16-128 μg/ml, for oxacillin becoming 16-64/32-128 μg/mL and reduced by ≥4-fold, evidencing a synergistic effect as defined by a FICI and FBCI of ≤ 0.5 except and in most of MRSA tested were reduced by ≥4-fold videncing a synergistic effect as defined by a FICI and FBCI of ≤ 0.5 except MRSA 10, 13, and 16 (FBCI ≥ 0.75), respectively (Table 3).

Samples Agent MIC/MBC (μg/ml) FIC/FBC FICI/FBCI2 Outcome
Alone Combination1
MSSA ATCC 25923 3 Baicalein 128/256 32/64 0.25/0.25 0.75/0.5 Additive/   Synergistic
Ampicillin 16-Aug 4-Apr 0.5/0.25
MRSA ATCC 33591 4 Baicalein 256/512 64/128 0.25/0.25 0.375/0.3125 Synergistic/ Synergistic
Ampicillin 512/2048 64/128 0.125/0.0625
VRSA 3A0635 Baicalein 128/512 32/64 0.25/0.125 0.5/0.25 Synergistic/  Synergistic  
Ampicillin 1024/2048 256/256 0.25/0.125
VRSA 3A0666 Baicalein 64/64 16-Aug 0.125/0.25 0.375/0.375 Synergistic/   Synergistic
Ampicillin 64/256 16/32 0.25/0.125
MSSA 17 Baicalein 128/128 16/32 0.125/0.25 0.375/0.5 Synergistic/  Synergistic
Ampicillin 512/1024 128/256 0.25/0.25
MSSA 2 Baicalein 256/512 64/128 0.25/0.25 0.5/0.5 Synergistic/ Synergistic
Ampicillin 256/512 64/128 0.25/0.25
MRSA 18 Baicalein 256/512 64/128 0.25/0.25 0.5/0.5 Synergistic/ Synergistic
Ampicillin 128/256 32/64 0.25/0.25
MRSA 2 Baicalein 128/512 32/64 0.25/0.125 0.375/0.375 Synergistic/   Synergistic
Ampicillin 128/256 16/64 0.125/0.25
MRSA 3 Baicalein 64/256 16/32 0.25/0.125 0.5/0.25 Synergistic/ Synergistic
Ampicillin 128/512 32/64 0.25/0.125
MRSA 4 Baicalein 64/128 16/32 0.25/0.25 0.5/0.5 Synergistic/  Synergistic
Ampicillin 256/512 64/128 0.25/0.25
MRSA 5 Baicalein 256/512 64/128 0.25/0.25 0.5/0.5 Synergistic/ Synergistic
Ampicillin 128/512 32/128 0.25/0.25
MRSA 6 Baicalein 256/512 64/128 0.25/0.25 0.5/0.5 Synergistic/
Ampicillin 64/128 16/32 0.25/0.25 Synergistic
MRSA 7 Baicalein 64/128 Aug-32 0.125/0.25 0.375/0.5 Synergistic/
Ampicillin 128/256 32/64 0.25/0.25 Synergistic
MRSA 8 Baicalein 128/256 32/64 0.25/0.25 0.5/0.5 Synergistic/   Synergistic
Ampicillin 256/512 64/128 0.25/0.25
MRSA 9 Baicalein 256/512 32/128 0.125/0.25 0.375/0.5 Synergistic/   Synergistic
Ampicillin 64/128 16/32 0.25/0.25
MRSA 10 Baicalein 256/256 64/128 0.25/0.5 0.5/0.75 Synergistic/   Additive
Ampicillin 128/256 32/64 0.25/0.25
MRSA 11 Baicalein 64/128 16/32 0.25/0.25 0.5/0.5 Synergistic/   Synergistic
Ampicillin 64/128 16/32 0.25/0.25
MRSA 12 Baicalein 64/64 16/16 0.25/0.25 0.375/0.5 Synergistic/
Ampicillin 256/256 32/64 0.125/0.25 Synergistic
MRSA 13 Baicalein 256/256 64/128 0.25/0.5 0.5/0.75 Synergistic/   Additive
Ampicillin 128/256 32/64 0.25/0.25
MRSA 14 Baicalein 256/512 64/128 0.25/0.25 0.5/0.5 Synergistic/ Synergistic
Ampicillin 128/256 32/64 0.25/0.25
MRSA 15 Baicalein 128/128 32/32 0.25/0.25 0.5/0.5 Synergistic/
Ampicillin 64/128 16/32 0.25/0.25 Synergistic
MRSA 16 Baicalein 256/512 64/128 0.25/0.25 0.5/0.75 Synergistic/   Additive
Ampicillin 128/512 32/64 0.25/0.125

Table 3: Synergistic effects of baicalein with ampicillin in isolated MRSA, VRSA, MSSA, and some of reference bacteria;1The MIC and MBC of baicalein with ampicillin; 2 The FIC index; 3MSSA (ATCC 25923): reference strain Methicillin-sensitive Staphylococcus aureus;4MRSA (ATCC 33591): reference strain Methicillin-resistant Staphylococcus aureus;5VRSA 3A063: Vancomycin-resistant Staphylococcus aureus isolated a clinic;6VRSA 3A066 : Vancomycin-resistant Staphylococcus aureus isolated a clinic;7MSSA (1, 2): Methicillin-sensitive Staphylococcus aureus isolated a clinic;8MRSA (1-16): Methicillin-resistant Staphylococcus aureus isolated a clinic.

The combination of vancomycin and baicalein resulted in a reduction against isolates MRSA 1-16, with the MICs/MBCs values of 16-64/32-128 μg/ml, for vancomycin becoming 0.125-0.5/0.25-1 μg/ml and reduced by ≥4-fold, evidencing a synergistic effect as defined by a FICI and FBCI of ≤ 0.5 except MRSA 8 and 15 of additive (FICI ≥ 0.75) and MRSA 4, 10, 12, 13, and 15 of additive (FBCI ≥ 0.625) and for isolates VRSA 1-2 and MSSA 1-2, with the MICs/MBCs of 16/32 or 32/64 μg/ml and 32/64 or 64/128, for vancomycin becoming 8/16 μg/ml and 0.25/0.5 μg/ml and reduced by ≥4-fold, evidencing a synergistic effect as defined by a FICI and FBCI of ≤ 0.5 except VRSA3A066 and MSSA 1 of additive (FBCI ≥ 0.75) (Table 4).

Samples Agent MIC/MBC (μg/ml) FIC/FBC FICI/FBCI2 Outcome
Alone Combination1
MSSA ATCC 25923 3 Baicalein 128/256 32/64 0.25/0.25 0.5/0.75 Synergistic/  Additive
Vancomycin 0.5/0.5 0.125/0.25 0.25/0.5
MRSA ATCC 33591 4 Baicalein 256/512 64/128 0.25/0.25 0.5/0.5 Synergistic/  Synergistic
Vancomycin 4-Feb 0.5/1 0.25/0.25
VRSA 3A0633 Baicalein 128/512 32/64 0.25/0.125 0.5/0.375 Synergistic/    Synergistic
Vancomycin 32/64 16-Aug 0.25/0.25
VRSA 3A0664 Baicalein 64/64 16/32 0.25/0.5 0.5/0.75 Synergistic/  Additive
Vancomycin 32/64 16-Aug 0.25/0.25
MSSA 1 Baicalein 128/128 32/64 0.25/0.5 0.5/0.75 Synergistic/
Vancomycin 2-Jan 0.25/0.5 0.25/0.25 Additive
MSSA 2 Baicalein 256/512 64/128 0.25/0.25 0.5/0.5 Synergistic/  Synergistic
Vancomycin 2-Jan 0.25/0.5 0.25/0.25
MRSA 1 Baicalein 256/512 64/128 0.25/0.25 0.5/0.5 Synergistic/
Vancomycin 2-Jan 0.25/0.5 0.25/0.25 Synergistic
MRSA 2 Baicalein 128/512 32/64 0.25/0.125 0.5/0.25 Synergistic/  Synergistic 
Vancomycin 4-Jan 0.25/0.5 0.25/0.125
MRSA 3 Baicalein 64/256 16/32 0.25/0.125 0.5/0.375 Synergistic/
Vancomycin 4-Feb 0.5/1 0.25/0.25 Synergistic
MRSA 4 Baicalein 64/128 16/32 0.25/0.25 0.5/0.75 Synergistic/  Additive
Vancomycin 1-Jan 0.25/0.5 0.25/0.5
MRSA 5 Baicalein 256/512 32/64 0.125/0.125 0.375/0.375 Synergistic/ Synergistic
Vancomycin 2-Jan 0.25/0.5 0.25/0.25
MRSA 6 Baicalein 256/512 64/128 0.25/0.25 0.5/0.5 Synergistic/   Synergistic
Vancomycin 2-Jan 0.25/0.5 0.25/0.25
MRSA 7 Baicalein 64/128 16/32 0.25/0.25 0.5/0.5 Synergistic/ Synergistic
Vancomycin 2-Jan 0.25/0.5 0.25/0.25
MRSA 8 Baicalein 128/256 32/64 0.25/0.25 0.75/0.5 Additive/ Synergistic
Vancomycin 4-Jan 0.5/1 0.5/0.25
MRSA 9 Baicalein 256/512 64/128 0.25/0.25 0.5/0.5 Synergistic/  Synergistic
Vancomycin 2-Jan 0.25/0.5 0.25/0.25
MRSA 10 Baicalein 256/256 64/128 0.25/0.5 0.5/0.625 Synergistic/   Additive
Vancomycin 0.5/2 0.125/0.25 0.25/0.125
MRSA 11 Baicalein 64/128 16/32 0.25/0.25 0.5/0.5 Synergistic/   Synergistic
Vancomycin 2-Jan 0.25/0.5 0.25/0.25
MRSA 12 Baicalein 64/64 16/32 0.25/0.5 0.5/0.625 Synergistic/  Additive
Vancomycin 0.5/4 0.125/0.5 0.25/0.125
MRSA 13 Baicalein 256/256 64/128 0.25/0.5 0.5/0.75 Synergistic/    Additive
Vancomycin 2-Jan 0.25/0.5 0.25/0.25
MRSA 14 Baicalein 256/512 64/128 0.25/0.25 0.5/0.375 Synergistic/ Synergistic
Vancomycin 4-Jan 0.25/0.5 0.25/0.125
MRSA 15 Baicalein 128/128 32/64 0.25/0.5 0.75/0.75 Additive/  Additive
Vancomycin 4-Jan 0.25/1 0.5/0.25
MRSA 16 Baicalein 256/512 64/128 0.25/0.25 0.5/0.5 Synergistic/  Synergistic
Vancomycin 0.5/1 0.125/0.25 0.25/0.25

Table 4: Synergistic effects of baicalein with vancomycin in isolated MRSA, VRSA, MSSA, and some of reference bacteria;1.The MIC and MBC of baicalein with vancomycin; 2 the FIC index; 3MSSA (ATCC 25923): reference strain Methicillin-sensitive Staphylococcus aureus;4MRSA (ATCC 33591): reference strain Methicillin-resistant Staphylococcus aureus;5VRSA 3A063: Vancomycin-resistant Staphylococcus aureus isolated a clinic;6VRSA 3A066 : Vancomycin-resistant Staphylococcus aureus isolated a clinic;7MSSA (1, 2): Methicillin-sensitive Staphylococcus aureus isolated a clinic;8MRSA (1-16): Methicillin-resistant Staphylococcus aureus isolated a clinic.

Time-kill curves

The effects of baicalein administered in combination with oxacillin and/or ampicillin and/or vancomycin against standard (MSSA and MRSA) and clinical isolates of MSSA (1, 2), VRSA (1,2), and MRSA (MRSA 1-16) were confirmed by time-kill curve experiments (Figures 1-4). Cultures of each strain of bacteria with a cell density of 106 CFU/mL were exposed to the MIC of baicalein and antibiotics alone or baicalein (1/2 MIC) with oxacillin (1/2 MIC) or ampicillin (1/2 MIC), and vancomycin (1/2 MIC). We observed that 30 minutes of baicalein treatment with ampicillin or oxacillin, vancomycin resulted in an increased rate of killing as compared to that observed with baicalein (MIC) alone. A profound bactericidal effect was exerted when a combination of drugs was utilized. The growth of the tested bacteria was completely attenuated after 2-5 h of treatment with the 1/2 MIC of baicalein, regardless of whether it was administered alone or with oxacillin (1/2 MIC) or ampicillin (1/2 MIC), or vancomycin (1/2 MIC) (Figures 1-4).

chemotherapy-vancomycin-stains

Figure 1: Time-kill curves of MIC or 1/2 MIC of bicalein, ampicillin (AMP), oxacillin (OXA), and vancomycin (VAN) alone and its combination with MIC50 of AMP or OXA, and VAN against MSSA 1, MSSA 2, VRSA 1, and VRSA 2 isolates and reference stains, MSSA ATCC25923 and MRSA ATCC33591. Bacteria were incubated with MIC of baicalein (), AMP, OXA, and VAN, and 1/2 MIC of baicalein+ 1/2 MIC of AMP (○), 1/2 MIC of baicalein + 1/2 MIC of OXA (), and 1/2 MIC of baicalein + 1/2 MIC of VAN () over time. CFU: Colony-Forming Units.

chemotherapy-kill-curves-Bacteria

Figure 2: Time-kill curves of MIC or 1/2 MIC of bicalein, ampicillin (AMP), oxacillin (OXA), and vancomycin (VAN) alone and its combination with 1/2 MIC of AMP or OXA, and VAN against MRSA 1, 2, 3, 4, 5, and 6 isolates. Bacteria were incubated with MIC of bicalein (), AMP, OXA, and VAN, and 1/2 MIC of bicalein + 1/2 MIC of AMP (○), 1/2 MIC of bicalein + 1/2 MIC of OXA (), and 1/2 MIC of bicalein + 1/2 MIC of VAN () over time. CFU: Colony- Forming Units.

chemotherapy-Colony-Forming-bicalein

Figure 3: Time-kill curves of MIC or 1/2 MIC of baicalein, ampicillin (AMP), oxacillin (OXA), and vancomycin (VAN) alone and its combination with 1/2 MIC of AMP or OXA, and VAN against MRSA 7, 8, 9, 10, 11, and 12 isolates. Bacteria were incubated with MIC of bicalein (), AMP, OXA, and VAN, and 1/2 MIC of bicalein + 1/2 MIC of AMP (○), 1/2 MIC of bicalein + 1/2 MIC of OXA (), and 1/2 MIC of bicalein + 1/2 MIC of VAN () over time. CFU: Colony-Forming Units.

chemotherapy-Colony-Forming-bicalein

Figure 4: Time-kill curves of MIC or 1/2 MIC of bicalein, ampicillin (AMP), oxacillin (OXA), and vancomycin (VAN) alone and its combination with 1/2 MIC of AMP or OXA, and VAN against MRSA 13, 14, 15, and 16 isolates. Bacteria were incubated with MIC of bicalein (), AMP (○), OXA (), and VAN (), and 1/2 MIC of bicalein + 1/2 MIC of AMP (), 1/2 MIC of bicalein + 1/2 MIC of OXA (○), and 1/2 MIC of bicalein + 1/2 MIC of VAN () over time. CFU: Colony-Forming Units.

Discussion

Many researchers are studying natural products that could be used as antibiotics against MRSA, and are employing novel dosing regimens and antimicrobials that would be advantageous for combating the therapeutic problems associated with S. aureus [8,11,12,21,24]. The baicalein exhibited inhibitory activities against isolates MSSA, MRSA, VRSA, and reference stains. The baicalein showed antibacteial activity against isolates MRSA 1-16 in MICs range of 64-256 μg/ml and MBCs range of 64-512 μg/mL, and VRSA 1 and 2 in MICs range of 64-128 μg/ml and in MBCs range of 64-512 μg/ml, respectively. The baicalein showed the strongest activity against VRSA 3A063, MRSA 3,4,7 and 12 (MICs values 64 μg/mL and MBCs values 64-128 μg/ml). The MIC50 and MIC90 values of baicalein for MRSA 1-16 isolates were 16-64 μg/ml and 64-256 μg/ml, respectively.

One potential choice is a flavone called baicalein, an active ingredient found in Scutellaria baicalensis Georgi., which is one of the most popular and multi-purpose herb used for the treatment of bacterial and viral infections [16,18,20,21,25]. In this study, the baicalein showed strong bacterial activity on MRSA and VRSA.

Evaluation of in vivo effectiveness of the antimicrobial combinations is necessary to generate data that can be extrapolated to the clinical situation as well as to predict relevant concentration of optimal dosing regimens for both agents of the combinations [26,27]. That combination therapy proceeds by different pathways according to the antibacterial agent used against pathogenic infections [28]. The most common combination strategy is to use drugs, each of which inhibits a different bacterial pathway. In the present study, we chose ampicillin, oxacillin, and vancomycin as the synthesis of cell walls in susceptible microbes by inhibiting peptidoglycan synthesis. Vancomycin has used treatment of serious infections caused by susceptible organisms resistant to penicillins (methicillin-resistant S. aureus) and multi resistant Staphylococcus epidermidis (MRSE) or in individuals with serious allergy to penicillins [4,5,27,29]. The combination of oxacillin and baicalein resulted in a reduction in the MICs/MBCs for isolates VRSA 1-2 by ≥4-fold, evidencing a synergistic effect as defined by a FICI and FBCI of ≤ 0.5 and MRSA 1-16 reduced by ≥4-fold, evidencing a synergistic effect as defined by a FICI and FBCI of ≤ 0.5 except MRSA 7 of additive (FICI ≥ 0.625) and MRSA 10, 12, 13, and 15 of additive (FBCI ≥ 0.75). The combination of ampicillin and baicalein resulted in a reduction in the MICs/MBCs for isolates VRSA 1-2 by ≥4-fold, evidencing a synergistic effect as defined by a FICI and FBCI of ≤ 0.5 and MRSA 1-16 reduced by ≥4-fold, evidencing a synergistic effect as defined by a FICI and FBCI of ≤ 0.5 except and in most of MRSA tested were reduced by ≥4-fold evidencing a synergistic effect as defined by a FICI and FBCI of ≤ 0.5 except MRSA 10, 13, and 16 (FBCI ≥ 0.75), respectively. The combination of vancomycin and baicalein resulted in a reduction against isolates MRSA 1-16 reduced by ≥4-fold, evidencing a synergistic effect as defined by a FICI and FBCI of ≤ 0.5 except MRSA 8 and 15 of additive (FICI ≥ 0.75) and MRSA 4, 10, 12, 13, and 15 of additive (FBCI ≥ 0.625) and VRSA 1-2 reduced by ≥4-fold, evidencing a synergistic effect as defined by a FICI and FBCI of ≤ 0.5 except VRSA3A066 of additive (FBCI ≥ 0.75). Synergy of baicalein associated with gentamicin against vancomycin-resistant Enterococcus has also been reported [25]. The synergistic actions of baicalein on MRSA may therefore involve other mechanisms of action such bacterial efflux pumps inhibition different from TetK, penicillin-binding proteins or interfering with the integrity of the cell wall [21,22].

Phytochemical constituents such as alkaloids, flavonoids, tannins, phenols, saponins, and several other aromatic compounds are secondary metabolites of plants that serve a defence mechanism against prediction by many microorganisms, insects and other herbivores [11-13,20,24]. The compounds in the flavonol, flavan-3-ol and flavone classes have been shown to inhibit energy metabolism (through ATP synthase inhibition) [30-32]. It has been reported that some plant derived compounds can improve the in vitro activity of some cell-wall inhibiting antibiotics by directly attacking the same target site, that is, peptidoglycan [33-35]. Some studies have shown that flavone derivatives are inhibitors of the NorA multidrug resistance pump in Staphylococcus aureus [22]. Baicalein acts as inhibitors of other bacterial resistant related enzymes such as methyl transferases associated to aminoglycosides resistance [36]. Flavonoid complexes attach with extra cellular soluble protein and with bacterial cell wall [37].

The effects of baicalein administered in combination with oxacillin and/or ampicillin and/or vancomycin against clinical isolates of VRSA and MRSA were confirmed by time-kill curve experiments. The timekill curve of baicalein showed completely attenuated after 2-5 h of treatment and an increased rate of killing as compared to that observed with baicalein alone. A profound bactericidal effect was exerted when a combination of drugs was utilized.

In conclusion, our results of the antibacterial activity showed that baicalein exhibited strong inhibitory activities against isolates MRSA and VRSA. The combination effects of baicalein with antibiotics were synergistic effect by FIC/FBC index <0.5 against most of tested clinic isolated MRSA and VRSA. The more the antibacterial action and cell wall synthesis inhibition increased when used in combination baicalein with oxacillin and/or vancomycin. Baicalein is expected to be recognized as natural sources for the development of new functional drugs against multi-resistant S. aureus, MRSA and VRSA.

Acknowledgements

This work was supported by a Korea Research Foundation Grant funded by the Korean Government (KRF-2009-0075707).

References

  1. Corey GR (2009) Staphylococcus aureus bloodstream infections: definitions and treatment. Clin Infect Dis 48: S254-259.
  2. Petti CA, Jr. Fowler VG (2003) Staphylococcus aureusbacteremia and endocarditis. CardiolClin 21:219-233
  3. Defres S, Marwick C, Nathwani D (2009) MRSA as a cause of lung infection including airway infection, community-acquired pneumonia and hospital-acquired pneumonia. EurRespir J 34: 1470-1476
  4. Levine DP (2008)Vancomycin: understanding its past and preserving its future. South Med J101: 284-291.
  5. Moravvej Z, Estaji F, Askari E, Solhjou K, Nasab MN, et al. (2013) Update on the global number of vancomycin-resistant Staphylococcus aureus (VRSA) strains. Int J Antimicrob Agents42: 370-371.
  6. Huang CH, Chen YH (2013)The detection and clinical impact of vancomycin MIC among patients with methicillin-resistant Staphylococcus aureusbacteremia. J MicrobiolImmunol Infect 46: 315-316.
  7. Hsu DI, Hidayat LK, Quist R, Hindler J, Karlsson A, et al. (2008) Comparison of method-specific vancomycin minimum inhibitory concentration values and their predictability for treatment outcome of methicillin-resistant Staphylococcus aureus (MRSA) infections. Int J Antimicrob Agents 32: 378-385.
  8. Aqil F, Khan MS, Osais M, Ahmad I (2005) Effect of certain bioactive plant extracts on clinical isolates of beta-lactamase producing methicillin-resistant Staphylococcus aureus. J Basic Microbiol 45: 106-114.
  9. Eloff JN (1998) Which extractant should be used for the screening and isolation of antimicrobial components from plants?. J Ethnopharmacol 60: 1-8.
  10. Parekh J, Chanda SV (2007) In vitro antimicrobial activity and phytochemical analysis of some Indian medicinal plants. Turkey J Biol 31: 53-58.
  11. Hatano T, Shintani Y, Aga Y, Shiota S, Tsuchiya T, et al. (2000) Phenolic constituents of licorice. VIII. Structures of glicophenone and glicoisoflavanone, and effects of licoricephenolics on methicillin-resistant Staphylococcus aureus. Chem Pharm Bull 48: 1286-1292.
  12. Fukai T, Marumo A, Kaitou K, Kanda T, Nomura T (2000) Antimicrobial activity of licorice flavonoids against methicillin-resistant Staphylococcus aureus. Fitoterapia 73: 536-539.
  13. Tripoli E, Guardia ML, Giammanco S, Majo DD, Giammanco M (2007) Citrus flavonoids: molecular structure, biological activity and nutritional properties. Food Chem 104: 466-479.
  14. Mahady GB (2005) Medicinal plants for the prevention and treatment of bacterial infections. Curr pharm des 11: 2405-24027
  15. Wang N, Ren D, Deng S, Yang X (2014) Differential effects of baicalein and its sulfated derivatives in inhibiting proliferation of human breast cancer MCF-7 cells. ChemBiol Interact14: 99-108.
  16. Jang EJ, Cha SM, Choi SM, Cha JD (2014) Combination effects of baicalein with antibiotics against oral pathogens. Arch Oral Biol 59 : 1233-1241.
  17. Chen F, Zhuang M, Peng J, Wang X, Huang T, et al. (2014) Baicalein inhibits migration and invasion of gastric cancer cells through suppression of the TGF-β signaling pathway. Mol Med Rep 5:
  18. Ding Y, Dou J, Teng Z, Yu J, Wang T, et al. (2014) antiviral activity of baicalein against influenza A (H1N1/H3N2) virus in cell culture and in mice and its inhibition of neuraminidase. Arch Virol 31:
  19. Fan GW, Zhang Y, Jiang X, Zhu Y, Wang B, et al. (2013) Anti-inflammatory activity of baicalein in LPS-stimulated RAW264.7 macrophages via estrogen receptor and NF-κB-dependent pathways. Inflammation 36 : 1584-1591.
  20. Yang D, Hu H, Huang S, Chaumont JP, Millet J (2000) Study on the inhibitory activity, in vitro of baicalein and baicalin against skin fungi and bacteria. Zhong Yao Cai 23 : 272-274.
  21. Fujita M, Shiota S, Kuroda T, Hatano T, Yoshida T, et al. (2005) Remarkable synergies between baicalein and tetracycline and baicalein and beta-lactams against methicillin-resistant Staphylococcus aureus. MicrobiolImmunol49 :391-396.
  22. Chan BC, Ip M, Lau CB, Lui SL, Jolivalt C, et al. (2011) Synergistic effects of baicalein with ciprofloxacin against NorA over-expressed methicillin-resistant Staphylococcus aureus (MRSA) and inhibition of MRSA pyruvate kinase. J Ethnopharmacol 137 : 767-773.
  23. Cha JD, Moon SE, Kim JY, Jung EK, Lee YS (2009) Antibacterial activity of sophoraflavanone G isolated from the roots of Sophoraflavescens against methicillin-resistant Staphylococcus aureus. Phytother Res 23 : 1326-1331.
  24. Jacqueline C, Caillon J, Le Mabecque V, Miegeville AF, Donnio PY, et al. (2003) In vitro activity of linezolid alone and in combination with gentamicin, vancomycin or rifampicin against methicillin-resistant Staphylococcus aureus by time-kill curve methods. J AntimicrobChem 51: 857-864.
  25. Chang PC, Li HY, Tang HJ, Liu JW, Wang JJ, et al. (2007) In vitro synergy of baicalein and gentamicin against vancomycin-resistant Enterococcus. J MicrobiolImmunol Infect 40 :56-61.
  26. Qin R, Xiao K, Li B, Jiang W, Peng W, et al. (2013) The combination of catechin and epicatechingallate from Fructuscrataegi potentiates beta-lactam antibiotics against methicillin-resistant Staphylococcus aureus (MRSA) in vitro and in vivo. Int J MolSci 14: 1802-1821.
  27. Périchon B, Courvalin P (2006)Synersism between beta-lactams and glycopeptides against VanA-type methicillin-resistant Staphylococcus aureus and heterologous expression of the vanA operon. Antimicrob Agents Chemother 50: 3622-3630.
  28. Seesom W, Jaratrungtawee A, Suksumran S, Mekseepralard C, Ratananukul P, et al. (2013) Antileptospiral activity of xanthones from Garciniamangostana and synergy of gamma-mangostin with penicillin G. BMC Complement Altern Med13: 182.
  29. Lee JY, Oh WS, Ko KS,Heo ST, Moon CS, et al. (2006) Synergy of arbekacin based combinations against vancomycin hetero-intermediate Staphylococcus aureus. J Korean Med Sci 21:188-192.
  30. Poór M, Veres B, Jakus PB, Antus C, Montskó G, et al. (2014) Flavonoid diosmetin increases ATP levels in kidney cells and relieves ATP depleting effect of ochratoxin A. J PhotochemPhotobiol B 132:1-9.
  31. Ahmad Z, Ahmad M, Okafor F, Jones J, Abunameh A, et al. (2012) Effect of structural modulation of polyphenolic compounds on the inhibition of Escherichia coli ATP synthase. Int J BiolMacromol 50 :476-486.
  32. Ahmad Z, Laughlin TF (2010) Medicinal chemistry of ATP synthase: a potential drug target of dietary polyphenols and amphibian antimicrobial peptides. Curr Med Chem17 :2822-2836.
  33. Maltezou HC, Giamarellou H (2006) Community-acquired methicillin-resistant Staphylococcus aureus infections. Int J Antimicrob Agents27: 87-96.
  34. Alekshun MN, Levy SB (2007) Molecular mechanisms of antibacterial multidrug resistance. Cell128: 1037-1050.
  35. Chen KM, Wu GL, Wang YH, Tian CT, Samaj J, et al. (2008) The block of intracellular calcium release affects the pollen tube development of Piceawilsonii by changing the deposition of cell wall components. Protoplasma 233 :39-49.
  36. Shin SC, Li C, Choi JS (2009) Effects of baicalein, an antioxidant, on the bioavailability of doxorubicin in rats: possible role of P-glycoprotein inhibition by baicalein. Pharmazie 64 : 579-583.
  37. Levinger O, Bikels-Goshen T, Landau E, Fichman M, Shapira R (2012)Epigallocatechingallate induces upregulation of the two-component VraSR system by evoking a cell wall stress response in Staphylococcus aureus. Environ Microbiol 78 : 7954-7959.
Citation: Young-Soo Lee,Eun-Kyung Jung and Jeong-Dan Cha (2015) Synergistic Effect between Baicalein and Antibiotics against Clinic Methicillin and Vancomycin-Resistant Staphylococcus aureus. Chemotherapy 3:141.

Copyright: © 2014 Jeong-Dan Cha. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Top